Lenalidomide and dexamethasone for acute light chain-induced renal failure: A phase II study

Haematologica

Volumn 100, Issue 3, 2015, Pages 385-391

  Ludwig, Heinz ^a   Rauch, Elisabeth ^a   Kuehr, Thomas ^b   Adam, Zdeněk ^c   Weißmann, Adalbert ^a   Kasparu, Hedwig ^d   Autzinger, Eva Maria ^a   Heintel, Daniel ^a   Greil, Richard ^e   Poenisch, Wolfram ^f   Müldür, Ercan ^a   Zojer, Niklas ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b Hospital Wels Grieskirchen   (Austria)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Hospital Salzburg   (Austria)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DEXAMETHASONE; LACTATE DEHYDROGENASE; LENALIDOMIDE; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ACUTE LIGHT CHAIN INDUCED RENAL FAILURE; ADULT; AGED; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CARDIOTOXICITY; CLINICAL ARTICLE; CONSTIPATION; DEATH; DIALYSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; INFECTION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; RISK FACTOR; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; PATHOLOGY; RENAL REPLACEMENT THERAPY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; ANEMIA; DEXAMETHASONE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RENAL DIALYSIS; SURVIVAL ANALYSIS; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84924723629     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.115204     Document Type: Article

References (34)

1. Haynes R, Leung N, Kyle R, Winearls CG. Myeloma kidney: improving clinical outcomes? Adv Chronic Kidney Dis. 2012; 19(5):342-351.
2. Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012; 120(22):4292-4295.
3. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001; 158(5):1859-1866.
4. Cserti C, Haspel R, Stowell C, Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion. 2007;47(3):511-514.
5. Iggo N, Winearls CG, Davies DR. The development of cast nephropathy in multiple myeloma. QJM. 1997;90(11):653-656
6. Murphy PT, Baldeo C, O'Kelly P, et al. Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma. Br J Haematol. 2014;165(6):890-891.
7. Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant. 2010;25(2):419-426.
8. Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25(1):195-200.
9. Leung N, Gertz M, Kyle RA, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol. 2012;7(12): 1964-1968.
10. Ainsworth NL, Marshall A, Hatcher H, Whitehead L, Whitfield GA, Earl HM. Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients. Ann Oncol. 2012;23(7):1845-1853.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
12. Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010; 28(30):4635-4641.
13. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma. 2009;9(4):302-306.
14. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20: 1467-1473.
15. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5): 1115-1123.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass. 1958;53:457-481.
17. Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Ass. 1952;47:583-621.
18. http://ctep.cancer.gov/protocolDevelopment /electronic_applications/docs/ctcaev3.pdf
19. Rota S, Mougenot B, Baudouin B, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore). 1987;66(2):126-137.
20. Cockwell P, Hutchison CA. Management options for cast nephropathy in multiple myeloma. Curr Opin Nephrol Hypertens. 2010;19(6):550-555.
21. Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129-1136.
22. Leung N, Nasr SH. Myeloma-related kidney disease. Adv Chronic Kidney Dis. 2014;21 (1):36-47.
23. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000; 65(3):175-181.
24. Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, et al. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leuk Lymphoma. 2011;52(12):2299-2303.
25. Scheid C, Sonneveld P, Schmidt-Wolf IG, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON- 65/GMMG-HD4 trial. Haematologica. 2014; 99(1):148-154.
26. Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009;27(36): 6086-6093.
27. San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22(4):842-9.
28. Tosi P, Zamagni E, Tacchetti P, et al. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol Blood Marrow Transplant. 2010; 16(8):1115-1121.
29. Dimopoulos M, Alegre A, Stadtmauer EA, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116 (16):3807-3814.
30. Benboubker L, Dimopoulos MA, et al. Continuous lenalidomide and dexamethasone for newly diagnosed multiple myeloma. N Engl J Med 2014;371(10):906-917.
31. Tosi P, Gamberi B, Castagnari B, et al. Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure. Mediterr J Hematol Infect Dis. 2013;5(1):e2013037.
32. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012; 18(8):2145-2163.
33. Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27(2):423-429.
34. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-- Medical Research Council Adult Leukemia Working Party. J Clin Oncol. 2005;23(36): 9219-9226.